Core Insights - CARGO Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing next-generation, potentially curative cell therapies for cancer patients [1][3] - The company will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, in San Francisco, California [1] - Gina Chapman, President and CEO, is scheduled to present on January 13 at 10:30 a.m. PT, with a live webcast available for interested parties [2] Company Overview - CARGO Therapeutics is developing innovative cell therapies to address limitations of existing treatments, including durability of effect, safety concerns, and supply reliability [3] - The company is evaluating firicabtagene autoleucel (firi-cel), an autologous CD22 CAR T-cell therapy, in a potentially pivotal Phase 2 clinical study for patients with relapsed or refractory large B-cell lymphoma [3] - CARGO's proprietary cell engineering platform aims to enhance CAR T-cell persistence and trafficking to tumor lesions, while also addressing tumor resistance and T-cell exhaustion [3] Pipeline and Technology - The CRG-023 program features a novel tri-specific CAR T with CD2 co-stimulation, targeting known causes of relapse to potentially create a best-in-class CAR T-cell therapy for various B-cell malignancies [3] - The goal of CARGO's therapies is to provide more patients with a durable complete response [3]
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference